{"id":"cyclosporine-0-010-eye-drops","brandName":"Cyclosporine 0.010% eye drops","genericName":"Cyclosporine 0.010% eye drops","companyId":"allergan","companyName":"Allergan","phase":"phase_2","status":"active","modality":"Small molecule","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Cyclosporine 0.010% eye drops, developed by Allergan, is a novel ophthalmic solution in Phase 3 for treating atopic keratoconjunctivitis. It has completed a Phase 2 trial in post-LASIK patients, showing promise in reducing inflammation and improving ocular surface health.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting calcineurin, cyclosporine prevents the transcription of interleukin-2 (IL-2), a key cytokine involved in T-cell proliferation. This results in a decrease in T-cell activation and subsequent immune response. This mechanism is particularly useful in preventing organ rejection in transplant patients.","oneSentence":"Cyclosporine is an immunosuppressant that inhibits calcineurin, thereby reducing T-cell activation.","_ai_confidence":"high"},"administration":{},"safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypertension"},{"rate":"5-15%","effect":"Nephrotoxicity"},{"rate":"5-10%","effect":"Diabetes mellitus"},{"rate":"5-10%","effect":"Hirsutism"},{"rate":"5-10%","effect":"Gingival hyperplasia"}]},"trials":[],"indications":{"approved":[{"name":"Prevention of organ rejection in transplant patients"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}